Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/28/2020 05/29/2020 06/01/2020 06/02/2020 06/03/2020 Date
120.22(c) 124.76(c) 123.4(c) 123.37(c) 119.03(c) Last
360 713 1 149 541 825 975 1 112 609 709 296 Volume
+0.93% +3.78% -1.09% -0.02% -3.52% Change
More quotes
Financials (USD)
Sales 2020 1 077 M - -
Net income 2020 302 M - -
Net cash position 2020 794 M - -
P/E ratio 2020 38,5x
Yield 2020 -
Sales 2021 1 359 M - -
Net income 2021 470 M - -
Net cash position 2021 1 376 M - -
P/E ratio 2021 25,6x
Yield 2021 -
Capitalization 11 054 M 11 054 M -
EV / Sales 2020 9,53x
EV / Sales 2021 7,12x
Nbr of Employees 750
Free-Float 95,5%
More Financials
Company
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA... 
Sector
Biotechnology & Medical Research
Calendar
06/02 | 11:00amPresentation
More about the company
Surperformance© ratings of Neurocrine Biosciences, In
Trading Rating : Investor Rating :
More Ratings
Latest news on NEUROCRINE BIOSCIENCES, IN
06/01ABBVIE : FDA Approves the First Oral Medication for the Management of Heavy Mens..
AQ
05/29ABBVIE : Gets FDA OK of Oriahnn for Fibroid-Related Heavy Menstrual Bleeding
DJ
05/26NEUROCRINE BIOSCIENCES : to Present at the Jefferies Virtual Healthcare Conferen..
PR
05/21NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submissi..
AQ
05/14NEUROCRINE BIOSCIENCES : to Present at the RBC Capital Markets 2020 Global Healt..
PR
05/14NEUROCRINE BIOSCIENCES : to Present Data from its Movement Disorder Portfolio on..
AQ
05/06NEUROCRINE BIOSCIENCES : Management's Discussion and Analysis of Financial Condi..
AQ
05/06NEUROCRINE BIOSCIENCES INC : Results of Operations and Financial Condition, Fina..
AQ
05/06NEUROCRINE : 1Q Earnings Snapshot
AQ
05/06NEUROCRINE BIOSCIENCES : Reports First Quarter 2020 Financial Results
PR
05/05NEUROCRINE BIOSCIENCES : to Present at Bank of America Merrill Lynch Health Care..
PR
04/27NEUROCRINE BIOSCIENCES : Announces FDA Approval of Once-Daily ONGENTYS® (opicapo..
PU
04/27NEUROCRINE BIOSCIENCES : Announces FDA Approval of Once-Daily ONGENTYS® (opicapo..
PR
04/15NEUROCRINE BIOSCIENCES : Announces Conference Call and Webcast of First Quarter ..
PR
04/09NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers (form 8-K..
AQ
More news
News in other languages on NEUROCRINE BIOSCIENCES, IN
06/01ABBVIE : FDA Approves the First Oral Medication for the Management of Heavy Mens..
05/29ABBVIE : Gets FDA OK of Oriahnn for Fibroid-Related Heavy Menstrual Bleeding
05/26NEUROCRINE BIOSCIENCES : to Present at the Jefferies Virtual Healthcare Conferen..
05/21NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submissi..
05/14NEUROCRINE BIOSCIENCES : to Present at the RBC Capital Markets 2020 Global Healt..
More news
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, IN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 121,33 $
Last Close Price 119,03 $
Spread / Highest target 16,8%
Spread / Average Target 1,94%
Spread / Lowest Target -15,1%
EPS Revisions
Managers
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
William H. Rastetter Chairman
Matthew C. Abernethy Chief Financial Officer
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.14.77%11 054
GILEAD SCIENCES14.50%91 895
VERTEX PHARMACEUTICALS26.52%73 705
REGENERON PHARMACEUTICALS60.94%70 764
WUXI APPTEC CO., LTD.22.32%25 389
GENMAB A/S33.95%19 425